Ironwood Pharmaceuticals
IRWD
245 hedge funds and large institutions have $1.76B invested in Ironwood Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 92 increasing their positions, 82 reducing their positions, and 25 closing their positions.
5,940% more call options, than puts
Call options by funds: $604K | Put options by funds: $10K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
32% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 25
12% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 82
3% more funds holding
Funds holding: 239 → 245 (+6)
2.99% less ownership
Funds ownership: 113.77% → 110.78% (-3%)
13% less capital invested
Capital invested by funds: $2.02B → $1.76B (-$262M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$31.1M |
| 2 |
Man Group
London,
United Kingdom
|
+$9.5M |
| 3 |
ABG
Ally Bridge Group
New York
|
+$8.42M |
| 4 |
Millennium Management
New York
|
+$8.21M |
| 5 |
HF
HRT Financial
New York
|
+$7.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$38.4M |
| 2 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$34.1M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$28.6M |
| 4 |
BlackRock
New York
|
-$21.8M |
| 5 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$20.6M |
IRWD Hedge Fund Activity: Q3 2022 in Review
245 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q3 2022, worth a combined $1.76B — down 13% from $2.02B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new IRWD positions and 25 closed out — a net gain of 8 holders — while 92 added to existing stakes and 82 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $31.1M. The largest seller was Putnam Investments, cutting an estimated $38.4M.
- 245 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q3 2022, up from 239 in Q2 2022.
- Funds reported $1.76B of Ironwood Pharmaceuticals stock for Q3 2022, down 13% quarter-over-quarter.
- 33 funds opened new Ironwood Pharmaceuticals positions in Q3 2022 and 25 closed out, a net change of +8 holders.
- The largest Ironwood Pharmaceuticals buyer in Q3 2022 was Victory Capital Management, an estimated $31.1M added.
- The largest Ironwood Pharmaceuticals seller in Q3 2022 was Putnam Investments, an estimated $38.4M sold.
Based on aggregated 13F filings for Q3 2022.